Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study.
Samson SL, Gu F, Feldt-Rasmussen U, Zhang S, Yu Y, Witek P, Kalra P, Pedroncelli AM, Pultar P, Jabbour N, Paul M, Bolanowski M. Samson SL, et al. Among authors: pedroncelli am. Pituitary. 2021 Dec;24(6):887-903. doi: 10.1007/s11102-021-01161-4. Epub 2021 Jul 18. Pituitary. 2021. PMID: 34275099 Free PMC article. Clinical Trial.
Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study.
Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM. Findling JW, et al. Among authors: pedroncelli am. Endocrine. 2016 Nov;54(2):516-523. doi: 10.1007/s12020-016-0978-6. Epub 2016 May 21. Endocrine. 2016. PMID: 27209465 Free PMC article. Clinical Trial.
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R, Fleseriu M, Newell-Price J, Bertagna X, Findling J, Shimatsu A, Gu F, Auchus R, Leelawattana R, Lee EJ, Kim JH, Lacroix A, Laplanche A, O'Connell P, Tauchmanova L, Pedroncelli AM, Biller BMK; LINC 3 investigators. Pivonello R, et al. Among authors: pedroncelli am. Lancet Diabetes Endocrinol. 2020 Sep;8(9):748-761. doi: 10.1016/S2213-8587(20)30240-0. Epub 2020 Jul 27. Lancet Diabetes Endocrinol. 2020. PMID: 32730798 Clinical Trial.
Risk factors and management of pasireotide-associated hyperglycemia in acromegaly.
Gadelha MR, Gu F, Bronstein MD, Brue TC, Fleseriu M, Shimon I, van der Lely AJ, Ravichandran S, Kandra A, Pedroncelli AM, Colao AAL. Gadelha MR, et al. Among authors: pedroncelli am. Endocr Connect. 2020 Dec;9(12):1178-1190. doi: 10.1530/EC-20-0361. Endocr Connect. 2020. PMID: 33434154 Free PMC article.
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ. Gadelha M, et al. Among authors: pedroncelli am. J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2882-e2895. doi: 10.1210/clinem/dgac178. J Clin Endocrinol Metab. 2022. PMID: 35325149 Free PMC article. Clinical Trial.
Long-term efficacy and safety of osilodrostat in Cushing's disease: final results from a Phase II study with an optional extension phase (LINC 2).
Fleseriu M, Biller BMK, Bertherat J, Young J, Hatipoglu B, Arnaldi G, O'Connell P, Izquierdo M, Pedroncelli AM, Pivonello R. Fleseriu M, et al. Among authors: pedroncelli am. Pituitary. 2022 Dec;25(6):959-970. doi: 10.1007/s11102-022-01280-6. Epub 2022 Oct 11. Pituitary. 2022. PMID: 36219274 Free PMC article. Clinical Trial.
Long-term efficacy and safety of osilodrostat in patients with Cushing's disease: results from the LINC 4 study extension.
Gadelha M, Snyder PJ, Witek P, Bex M, Belaya Z, Turcu AF, Feelders RA, Heaney AP, Paul M, Pedroncelli AM, Auchus RJ. Gadelha M, et al. Among authors: pedroncelli am. Front Endocrinol (Lausanne). 2023 Aug 23;14:1236465. doi: 10.3389/fendo.2023.1236465. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37680892 Free PMC article.
33 results